Published in Neurosci Lett on August 10, 2012
Amide proton transfer imaging of adult diffuse gliomas: correlation with histopathological grades. Neuro Oncol (2013) 1.29
Natural killer cells eradicate galectin-1-deficient glioma in the absence of adaptive immunity. Cancer Res (2014) 0.91
Safety profile, efficacy, and biodistribution of a bicistronic high-capacity adenovirus vector encoding a combined immunostimulation and cytotoxic gene therapy as a prelude to a phase I clinical trial for glioblastoma. Toxicol Appl Pharmacol (2013) 0.90
Current status of gene therapy for brain tumors. Transl Res (2012) 0.90
Methods for gene transfer to the central nervous system. Adv Genet (2014) 0.88
Advances in diagnostic and treatment modalities for intracranial tumors. J Vet Intern Med (2014) 0.87
Strategies in gene therapy for glioblastoma. Cancers (Basel) (2013) 0.87
HERG K+ channel-dependent apoptosis and cell cycle arrest in human glioblastoma cells. PLoS One (2014) 0.83
Gene therapy for malignant glioma. Mol Cell Ther (2014) 0.83
The myeloid-binding peptide adenoviral vector enables multi-organ vascular endothelial gene targeting. Lab Invest (2014) 0.82
STAT3 Decoy Oligodeoxynucleotides-Loaded Solid Lipid Nanoparticles Induce Cell Death and Inhibit Invasion in Ovarian Cancer Cells. PLoS One (2015) 0.81
Combinatorial treatment with oncolytic adenovirus and helper-dependent adenovirus augments adenoviral cancer gene therapy. Mol Ther Oncolytics (2014) 0.79
Dendritic cell-based immunotherapy for glioma: multiple regimens and implications in clinical trials. Neurol Med Chir (Tokyo) (2013) 0.78
A systematic review and meta-analysis of gene therapy in animal models of cerebral glioma: why did promise not translate to human therapy? Evid Based Preclin Med (2015) 0.78
Improved Adeno-associated Viral Gene Transfer to Murine Glioma. J Genet Syndr Gene Ther (2013) 0.77
Gene Therapy for the Treatment of Neurological Disorders: Central Nervous System Neoplasms. Methods Mol Biol (2016) 0.76
A three-dimensional collagen scaffold cell culture system for screening anti-glioma therapeutics. Oncotarget (2016) 0.76
Induction of antigen-specific cytotoxic T-cell response by dendritic cells generated from ecto-mesenchymal stem cells infected with an adenovirus containing the MAGE-D4a gene. Oncol Lett (2016) 0.75
Stem cells as cellular vehicles for gene therapy against glioblastoma. Int J Clin Exp Med (2015) 0.75
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med (2005) 74.55
Tumor angiogenesis: therapeutic implications. N Engl J Med (1971) 35.36
MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med (2005) 29.65
Malignant gliomas in adults. N Engl J Med (2008) 20.54
Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev (2007) 17.20
Angiogenesis in brain tumours. Nat Rev Neurosci (2007) 6.82
Differentiated rat glial cell strain in tissue culture. Science (1968) 6.49
Cost of migration: invasion of malignant gliomas and implications for treatment. J Clin Oncol (2003) 5.28
Long-term survival with glioblastoma multiforme. Brain (2007) 4.51
Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol (2010) 4.23
Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme. Neuro Oncol (2005) 4.10
Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer (2010) 4.10
Epidemiology and molecular pathology of glioma. Nat Clin Pract Neurol (2006) 3.76
A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice. Genes Dev (1998) 3.68
Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clin Cancer Res (2010) 3.56
Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide. J Clin Oncol (2007) 3.23
Development of a novel mouse glioma model using lentiviral vectors. Nat Med (2009) 3.08
Self-regulation of growth in three dimensions. J Exp Med (1973) 2.87
Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression. J Neurooncol (2007) 2.85
HMGB1 mediates endogenous TLR2 activation and brain tumor regression. PLoS Med (2009) 2.56
Glial progenitors in adult white matter are driven to form malignant gliomas by platelet-derived growth factor-expressing retroviruses. J Neurosci (2006) 2.43
The molecular and genetic basis of neurological tumours. Nat Rev Cancer (2002) 2.41
Dose-dependent effects of platelet-derived growth factor-B on glial tumorigenesis. Cancer Res (2004) 2.36
Rat brain tumor models in experimental neuro-oncology: the C6, 9L, T9, RG2, F98, BT4C, RT-2 and CNS-1 gliomas. J Neurooncol (2009) 2.33
A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther (2000) 2.26
Current concepts and management of glioblastoma. Ann Neurol (2011) 2.23
AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study. Mol Ther (2004) 2.15
Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. J Clin Oncol (2007) 2.01
Morphological and immunochemical studies of rat glial tumors and clonal strains propagated in culture. J Neurosurg (1971) 1.92
Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res (1987) 1.87
Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab. Neurology (2011) 1.85
Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model. Cancer Res (2005) 1.74
Establishment, maintenance and in vitro and in vivo applications of primary human glioblastoma multiforme (GBM) xenograft models for translational biology studies and drug discovery. Curr Protoc Pharmacol (2011) 1.63
Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck. Clin Cancer Res (2010) 1.63
Adenoviral vectors expressing lymphotactin and interleukin 2 or lymphotactin and interleukin 12 synergize to facilitate tumor regression in murine breast cancer models. Hum Gene Ther (1999) 1.60
Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses. Hum Gene Ther (2000) 1.57
De novo induction of genetically engineered brain tumors in mice using plasmid DNA. Cancer Res (2009) 1.49
Advances in the genetics of glioblastoma: are we reaching critical mass? Nat Rev Neurol (2009) 1.48
Radioresponsive tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene therapy for malignant brain tumors. Cancer Gene Ther (2007) 1.46
Inflammatory and anti-glioma effects of an adenovirus expressing human soluble Fms-like tyrosine kinase 3 ligand (hsFlt3L): treatment with hsFlt3L inhibits intracranial glioma progression. Mol Ther (2004) 1.42
Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study. Neuro Oncol (2007) 1.38
Expression of interleukin-13 receptor alpha2 in glioblastoma multiforme: implications for targeted therapies. Cancer Res (2007) 1.33
Uncertainty in the translation of preclinical experiments to clinical trials. Why do most phase III clinical trials fail? Curr Gene Ther (2009) 1.33
Gene therapy-mediated delivery of targeted cytotoxins for glioma therapeutics. Proc Natl Acad Sci U S A (2010) 1.29
Novel anti-brain tumor cytotoxins specific for cancer cells. Nat Biotechnol (1998) 1.28
Designer therapies for glioblastoma multiforme. Ann N Y Acad Sci (2008) 1.28
Interleukin-13 receptor alpha 2, EphA2, and Fos-related antigen 1 as molecular denominators of high-grade astrocytomas and specific targets for combinatorial therapy. Clin Cancer Res (2008) 1.28
Polarization of naive T cells into Th1 or Th2 by distinct cytokine-driven murine dendritic cell populations: implications for immunotherapy. J Leukoc Biol (2005) 1.25
Interleukin-13 displaying retargeted oncolytic measles virus strains have significant activity against gliomas with improved specificity. Mol Ther (2008) 1.24
Adenovirus/herpes simplex-thymidine kinase/ganciclovir complex: preliminary results of a phase I trial in patients with recurrent malignant gliomas. J Neurooncol (2003) 1.23
Release of HMGB1 in response to proapoptotic glioma killing strategies: efficacy and neurotoxicity. Clin Cancer Res (2009) 1.22
Expression of glioma-associated antigens in pediatric brain stem and non-brain stem gliomas. J Neurooncol (2008) 1.15
Glioma oncoprotein Bcl2L12 inhibits the p53 tumor suppressor. Genes Dev (2010) 1.11
Aberrant receptor signaling in human malignant gliomas: mechanisms and therapeutic implications. Cancer Lett (2001) 1.11
The dual role of tumor necrosis factor (TNF) in cancer biology. Curr Med Chem (2010) 1.08
Interleukin 13 mutants of enhanced avidity toward the glioma-associated receptor, IL13Ralpha2. Neoplasia (2004) 1.07
Flt3L in combination with HSV1-TK-mediated gene therapy reverses brain tumor-induced behavioral deficits. Mol Ther (2008) 1.05
A novel pre-clinical in vivo mouse model for malignant brain tumor growth and invasion. J Neurooncol (2010) 1.03
A phase I trial of Ad.hIFN-beta gene therapy for glioma. Mol Ther (2008) 1.03
Integration and long-term expression in xenografted human glioblastoma cells using a plasmid-based transposon system. Mol Ther (2004) 1.03
B cells are critical to T-cell-mediated antitumor immunity induced by a combined immune-stimulatory/conditionally cytotoxic therapy for glioblastoma. Neoplasia (2011) 1.01
The role of TNF in cancer. Results Probl Cell Differ (2009) 1.01
Treatment of relapsed malignant glioma with an adenoviral vector containing the herpes simplex thymidine kinase gene followed by ganciclovir. Mol Ther (2003) 0.98
T cells as sources and targets of TNF: implications for immunity and autoimmunity. Curr Dir Autoimmun (2010) 0.96
Therapeutic efficacy of PUMA for malignant glioma cells regardless of p53 status. Hum Gene Ther (2005) 0.95
Morphology of malignant gliomas induced in rabbits by systemic application of N-methyl-N-nitrosourea. Z Neurol (1970) 0.95
Functionality of hypoxia-induced BAX expression in a human glioblastoma xenograft model. Cancer Gene Ther (2005) 0.91
Treatment of intracranial glioma with in situ interferon-gamma and tumor necrosis factor-alpha gene transfer. Cancer Gene Ther (2002) 0.89
Molecular changes in gliomas. Curr Opin Oncol (2004) 0.88
Sensing the microenvironment of the central nervous system: immune cells in the central nervous system and their pharmacological manipulation. Curr Opin Pharmacol (2008) 0.87
Immune response induced by retrovirus-mediated HSV-tk/GCV pharmacogene therapy in patients with glioblastoma multiforme. Gene Ther (2000) 0.86
Evaluation of combined vaccinia virus-mediated antitumor gene therapy with p53, IL-2, and IL-12 in a glioma model. Cancer Gene Ther (2000) 0.83
NKX2.2 suppresses self-renewal of glioma-initiating cells. Cancer Res (2010) 0.81
Magnetic resonance imaging-guided microdialysis cannula implantation in a spontaneous high-grade glioma murine model. J Pharm Sci (2011) 0.77
The Collaborative Cross, a community resource for the genetic analysis of complex traits. Nat Genet (2004) 9.37
Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression. J Neurooncol (2007) 2.85
HMGB1 mediates endogenous TLR2 activation and brain tumor regression. PLoS Med (2009) 2.56
Platelets mediate cytotoxic T lymphocyte-induced liver damage. Nat Med (2005) 2.19
Identification of RNF213 as a susceptibility gene for moyamoya disease and its possible role in vascular development. PLoS One (2011) 2.01
Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model. Cancer Res (2005) 1.74
Immune responses to adenovirus and adeno-associated vectors used for gene therapy of brain diseases: the role of immunological synapses in understanding the cell biology of neuroimmune interactions. Curr Gene Ther (2007) 1.55
In vivo mature immunological synapses forming SMACs mediate clearance of virally infected astrocytes from the brain. J Exp Med (2006) 1.52
Treg depletion inhibits efficacy of cancer immunotherapy: implications for clinical trials. PLoS One (2008) 1.49
Inflammatory and anti-glioma effects of an adenovirus expressing human soluble Fms-like tyrosine kinase 3 ligand (hsFlt3L): treatment with hsFlt3L inhibits intracranial glioma progression. Mol Ther (2004) 1.42
Regulatable gutless adenovirus vectors sustain inducible transgene expression in the brain in the presence of an immune response against adenoviruses. J Virol (2006) 1.41
One-year expression from high-capacity adenoviral vectors in the brains of animals with pre-existing anti-adenoviral immunity: clinical implications. Mol Ther (2007) 1.36
Uncertainty in the translation of preclinical experiments to clinical trials. Why do most phase III clinical trials fail? Curr Gene Ther (2009) 1.33
Fms-like tyrosine kinase 3 ligand recruits plasmacytoid dendritic cells to the brain. J Immunol (2006) 1.32
Flt3L and TK gene therapy eradicate multifocal glioma in a syngeneic glioblastoma model. Neuro Oncol (2007) 1.31
Gene therapy-mediated delivery of targeted cytotoxins for glioma therapeutics. Proc Natl Acad Sci U S A (2010) 1.29
Improved distribution of small molecules and viral vectors in the murine brain using a hollow fiber catheter. J Neurosurg (2007) 1.24
Antiglioma immunological memory in response to conditional cytotoxic/immune-stimulatory gene therapy: humoral and cellular immunity lead to tumor regression. Clin Cancer Res (2009) 1.24
Progress in gene therapy for neurological disorders. Nat Rev Neurol (2013) 1.22
Release of HMGB1 in response to proapoptotic glioma killing strategies: efficacy and neurotoxicity. Clin Cancer Res (2009) 1.22
Stability of lentiviral vector-mediated transgene expression in the brain in the presence of systemic antivector immune responses. Hum Gene Ther (2005) 1.20
Effects of ectopic decorin in modulating intracranial glioma progression in vivo, in a rat syngeneic model. Cancer Gene Ther (2004) 1.14
Effective high-capacity gutless adenoviral vectors mediate transgene expression in human glioma cells. Mol Ther (2006) 1.12
In vivo polarization of IFN-gamma at Kupfer and non-Kupfer immunological synapses during the clearance of virally infected brain cells. J Immunol (2008) 1.09
Combining cytotoxic and immune-mediated gene therapy to treat brain tumors. Curr Top Med Chem (2005) 1.09
A rare Asian founder polymorphism of Raptor may explain the high prevalence of Moyamoya disease among East Asians and its low prevalence among Caucasians. Environ Health Prev Med (2009) 1.08
Combined Flt3L/TK gene therapy induces immunological surveillance which mediates an immune response against a surrogate brain tumor neoantigen. Mol Ther (2011) 1.07
Gene transfer into rat brain using adenoviral vectors. Curr Protoc Neurosci (2010) 1.05
Flt3L in combination with HSV1-TK-mediated gene therapy reverses brain tumor-induced behavioral deficits. Mol Ther (2008) 1.05
Immunization against the transgene but not the TetON switch reduces expression from gutless adenoviral vectors in the brain. Mol Ther (2008) 1.05
Normalization of wound healing and diabetic markers in organ cultured human diabetic corneas by adenoviral delivery of c-Met gene. Invest Ophthalmol Vis Sci (2009) 1.05
Gene therapy for brain cancer: combination therapies provide enhanced efficacy and safety. Curr Gene Ther (2009) 1.04
Crossing the rubicon. Nat Biotechnol (2009) 1.03
Adenovirus binding to the coxsackievirus and adenovirus receptor or integrins is not required to elicit brain inflammation but is necessary to transduce specific neural cell types. J Virol (2002) 1.02
Gene therapy and targeted toxins for glioma. Curr Gene Ther (2005) 1.02
B cells are critical to T-cell-mediated antitumor immunity induced by a combined immune-stimulatory/conditionally cytotoxic therapy for glioblastoma. Neoplasia (2011) 1.01
Immunological thresholds in neurological gene therapy: highly efficient elimination of transduced cells might be related to the specific formation of immunological synapses between T cells and virus-infected brain cells. Neuron Glia Biol (2006) 1.00
Optimization of adenoviral vector-mediated transgene expression in the canine brain in vivo, and in canine glioma cells in vitro. Neuro Oncol (2007) 0.99
T cells' immunological synapses induce polarization of brain astrocytes in vivo and in vitro: a novel astrocyte response mechanism to cellular injury. PLoS One (2008) 0.99
Sequence effects of aminofluorene-modified DNA duplexes: thermodynamic and circular dichroism properties. Nucleic Acids Res (2006) 0.99
Development of a novel helper-dependent adenovirus-Epstein-Barr virus hybrid system for the stable transformation of mammalian cells. J Virol (2004) 0.98
Mutagenesis-induced, large fitness variations with an invariant arenavirus consensus genomic nucleotide sequence. J Virol (2005) 0.98
Gene therapy and targeted toxins for glioma. Curr Gene Ther (2011) 0.97
Engineering the brain tumor microenvironment enhances the efficacy of dendritic cell vaccination: implications for clinical trial design. Clin Cancer Res (2011) 0.96
Infiltrating CTLs in human glioblastoma establish immunological synapses with tumorigenic cells. Am J Pathol (2009) 0.95
Confirmation of an association of single-nucleotide polymorphism rs1333040 on 9p21 with familial and sporadic intracranial aneurysms in Japanese patients. Stroke (2010) 0.95